GRPH Company Profile and Key Details
Graphite Bio, Inc.
GRPH Stock Price Chart
Stock Price Today
Graphite Bio, Inc. (GRPH) stock declined over -2.75%, trading at $3.18 on NASDAQ, down from the previous close of $3.27. The stock opened at $3.20, fluctuating between $3.05 and $3.23 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Company Information
| Employees | 6 |
| Beta | 0.2 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Graphite Bio, Inc. (NASDAQ: GRPH) stock price is $3.18 in the last trading session. During the trading session, GRPH stock reached the peak price of $3.23 while $3.05 was the lowest point it dropped to. The percentage change in GRPH stock occurred in the recent session was -2.75% while the dollar amount for the price change in GRPH stock was -$0.09.
The NASDAQ listed GRPH is part of Biotechnology industry that operates in the broader Healthcare sector. Graphite Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Daniel Dever Ph.D.
Co-Founder & Head of Discovery Research
Dr. Jane Grogan Ph.D.
Chief Scientific Officer
Dr. Joshua Lehrer-Graiwer FACC, M.D.
Pres, Chief Executive Officer & Director
Mr. Jerry Cacia
Chief Technical Officer
Mr. Philip P. Gutry
Chief Bus. Officer
Dr. Maria Grazia Roncarolo M.D., Ph.D.
Academic Founder & Chair of Scientific Advisory Board
Dr. Christine Garrett P.M.P., Ph.D.
Chief of Staff & Senior Vice President of Operations
Ms. Julia Tran
Chief People Officer
Mr. Darren Hart B.S.N., J.D.
Senior Vice President of Devel.
Dr. Matthew Porteus M.D., Ph.D.
Scientific Founder & Advisory Board Member
Stephanie Yao
Executive Director of Investor Relations & Corporation Communications
Ms. Alethia Rene Young
Chief Financial Officer
GRPH's closing price is 4.26% higher than its 52-week low of $3.05 where as its distance from 52-week high of $29.82 is -89.34%.
Number of GRPH employees currently stands at 6.
Official Website of GRPH is: https://www.graphitebio.com
GRPH could be contacted at phone 650 484 0886 and can also be accessed through its website. GRPH operates from 201 Haskins Way, South San Francisco, CA 94080, United States.
GRPH stock volume for the day was 299.41K shares. The average number of GRPH shares traded daily for last 3 months was 40.96K.
The market value of GRPH currently stands at $185.19M with its latest stock price at $3.18 and 58.24M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com